Results 51 to 60 of about 10,848 (199)

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy

American Society of Nephrology. Clinical Journal
Visual Abstract Key Points Obinutuzumab induced more remission than rituximab at 12 months in patients with primary membranous nephropathy. Obinutuzumab shared a similar safety profile as rituximab in patients with primary membranous nephropathy ...
Xiao-Fan Hu, Mu-Yin Zhang, Jing Xu, Chen-Ni Gao, Xia-Lian Yu, Xiao Li, H. Ren, Wei-Ming Wang, Jing-Yuan Xie   +8 more
semanticscholar   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.

The Lancet Oncology
BACKGROUND The diffuse large B-cell lymphoma (DLBCL) variant of Richter transformation (DLBCL-RT) is typically chemoresistant with poor prognosis. Aiming to explore a chemotherapy-free treatment combination that triggers anti-tumour immune responses, we ...
Alessandra Tedeschi, A. Frustaci, A. Condoluci, M. Coscia, Roberto Chiarle, P. Zinzani, M. Motta, G. Gaidano, G. Quaresmini, L. Scarfò, G. Catania, M. Deodato, Rebecca Jones, V. Tabanelli, V. Griggio, G. Stussi, Angelica Calleri, K. Pini, R. Cairoli, Thorsten Zenz, A. Signori, E. Zucca, Davide Rossi, M. Montillo   +23 more
semanticscholar   +1 more source

Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation

Frontiers in Drug Safety and Regulation, 2023
Introduction: In December 2020, the Italian Medicines Agency (AIFA) in collaboration with the Italian Regional Centers of Pharmacovigilance evaluated four individual case safety reports (ICSRs) reporting obinutuzumab and non-overt disseminated ...
Giulia Valdiserra, Nadia Mores, Rosalba Elisabetta Rocchi, Laura Sottosanti, Patrizia Felicetti, Pasquale Marchione, Luca Laurenti, Alberto Fresa, Giampaolo Bucaneve, Emiliano Cappello, Marco Bonaso, Sara Ferraro, Irma Convertino, Marco Tuccori, Marco Tuccori   +14 more
doaj   +1 more source

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

British Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee, Eric J. Zhao, Cassidy Clemente‐Jones, Rebecca J. Deyell, Shahrad R. Rassekh, Anita Villani, Rosemarie Venier, Daniel Sinnett, Sylvie Langlois, Thai Hoa Tran, Thomas Sontag, Stephanie Grover, Scott Davidson, Nisha Kanwar, Winnie Lo, Erin Pleasance, Laura Williamson, Yaoqing Shen, Alina S. Gerrie, Kerry J. Savage, Laurie H. Sehn, Christopher P. Venner, Marco A. Marra, Janessa Laskin, Diego Villa   +24 more
wiley   +1 more source

Simultaneous determination of venetoclax and obinutuzumab by LC-MS/MS and its application to pharmacokinetic drug interaction studies [PDF]

Brazilian Journal of Pharmaceutical Sciences
A novel LC-MS/MS method was developed and validated for the simultaneous quantification of venetoclax and obinutuzumab in rat plasma and successfully applied to pharmacokinetic investigations in male wistar rats.
Modachakanahally K Pavithra, Hemavathi Nagaraju Deepakumari, Ere Vijaya Sekhar, Hosakere Doddarevanna Revanasiddappa, Razia Sulthana   +4 more
doaj   +2 more sources

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations

, 2016
Introduction: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody (MoAb) with a higher affinity for CD20 epitope. It was approved by the United States Food and Drug Administration (FDA) in November 2013 for use in combination ...
M. Sciumè, N. Orofino, A. Cortelezzi, G. Reda, R. Cassin, B. Fattizzo   +5 more
core   +1 more source

Baseline maximum standardised uptake value does not predict outcomes in high‐tumour‐burden follicular lymphoma treated with first‐line immunochemotherapy

British Journal of Haematology, EarlyView.
Baseline maximum standardised uptake value does not predict survival in high‐tumour‐burden follicular lymphoma treated with first‐line immunochemotherapy, but identifies patients at risk of histological transformation: no transformation occurred below the cohort median. Its role is to guide biopsy and surveillance rather than therapeutic stratification.
Ikram Bouguern, Zora Marjanovic, Elise Corre, Laure Ricard, Bénédicte Jonca, Fazia Kaoui, Zoé Van de Wyngaert, Paul Coppo, Mohamad Mohty, Florent Malard, Nicolas Stocker   +10 more
wiley   +1 more source

Disseminated Enteroviral Infection Associated with Obinutuzumab

, 2015
Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome.
Tony M. Korman, Michael Gilbertson, Vera Golder, Claire Dendle, Eric Morand, Stephen Opat   +5 more
core   +1 more source